- Home
- GLTO vs NCPL Comparison
GLTO vs NCPL Comparison
Compare GLTO & NCPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- NCPL
- Stock Information
- Founded
- GLTO 2011
- NCPL 1984
- Country
- GLTO Denmark
- NCPL United States
- Employees
- GLTO N/A
- NCPL N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- NCPL Investment Managers
- Sector
- GLTO Health Care
- NCPL Finance
- Exchange
- GLTO Nasdaq
- NCPL Nasdaq
- Market Cap
- GLTO 4.4M
- NCPL 4.3M
- IPO Year
- GLTO 2020
- NCPL N/A
- Fundamental
- Price
- GLTO $3.35
- NCPL $5.34
- Analyst Decision
- GLTO Buy
- NCPL
- Analyst Count
- GLTO 1
- NCPL 0
- Target Price
- GLTO $10.00
- NCPL N/A
- AVG Volume (30 Days)
- GLTO 18.8K
- NCPL 638.1K
- Earning Date
- GLTO 08-11-2025
- NCPL 07-28-2025
- Dividend Yield
- GLTO N/A
- NCPL N/A
- EPS Growth
- GLTO N/A
- NCPL N/A
- EPS
- GLTO N/A
- NCPL N/A
- Revenue
- GLTO N/A
- NCPL $812,612.00
- Revenue This Year
- GLTO N/A
- NCPL N/A
- Revenue Next Year
- GLTO N/A
- NCPL $101.16
- P/E Ratio
- GLTO N/A
- NCPL N/A
- Revenue Growth
- GLTO N/A
- NCPL N/A
- 52 Week Low
- GLTO $2.01
- NCPL $1.41
- 52 Week High
- GLTO $16.07
- NCPL $11.90
- Technical
- Relative Strength Index (RSI)
- GLTO 65.19
- NCPL 71.16
- Support Level
- GLTO $3.19
- NCPL $3.90
- Resistance Level
- GLTO $3.63
- NCPL $5.06
- Average True Range (ATR)
- GLTO 0.24
- NCPL 0.72
- MACD
- GLTO 0.01
- NCPL 0.18
- Stochastic Oscillator
- GLTO 79.37
- NCPL 69.64
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.